American Bio Medica

American Bio Medica Net Margin

Delisted

The Net Profit Margin of American Bio Medica (ABMC) as of Nov 20, 2026 is -154.44 %. In the previous year, Net Profit Margin was -20.87 % — a change of 639.82% (lower).

Net Margin

-154.44 %

YoY

639.82%

Last updated:

Net Profit Margin of American Bio Medica is 2022 -154.44 % . Net Profit Margin of American Bio Medica was 2021 -20.87 % . It decreases by 639.82% lower compared to the previous year.

American Bio Medica's net margin stands at -154.4%, down from -26.5% several years earlier.

The American Bio Medica Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2015
-5.27 USD
Jan 1, 2016
-6.15 USD
Jan 1, 2017
-11.09 USD
Jan 1, 2018
-26.55 USD
Jan 1, 2019
-18.63 USD
Jan 1, 2020
-19.19 USD
Jan 1, 2021
-20.87 USD
Jan 1, 2022
-154.44 USD
The American Bio Medica Net Margin history
YEARNet MarginYoY
-154.44 %+639.82%
-20.87 %+8.75%
-19.19 %+3.02%
-18.63 %-29.82%
-26.55 %+139.38%
-11.09 %+80.31%
-6.15 %+16.68%
-5.27 %-21.63%
-6.73 %+7,469.05%
-0.09 %-25.23%
-0.12 %+214.77%
-0.04 %-47.54%
-0.07 %-22.18%
-0.09 %+37.77%
-0.07 %-5.94%
-0.07 %-593.93%
0.01 %-149.51%
-0.03 %-232.31%
0.02 %-73.27%
0.08 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

American Bio Medica Stock analysis

What does American Bio Medica do? American Bio Medica Corp is a US-based company specializing in the development and manufacture of drug testing devices and diagnostic products. The company was founded in 1986 and is headquartered in Kinderhook, New York. Its business model involves developing and producing drug testing devices and diagnostic products used by government agencies, companies, and private customers worldwide. The company also operates a laboratory that conducts diagnostic tests for third parties. Its five business areas include drug tests, medication safety, diagnostics, biometrics, and forensics. The company's products include urine, saliva, and sweat drug tests, as well as medical devices to prevent prescription drug abuse and diagnostic products for various diseases. It also offers biometric instruments and systems for person identification and forensic products for crime investigation. American Bio Medica Corp has been publicly traded since 1992 and has received several awards for its products and innovations. The company is committed to research and development, quality assurance, and accuracy in its products. Overall, it is a leading company in the field of drug testing devices and diagnostic products and is expected to continue to evolve in the future. American Bio Medica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Bio Medica stock

Net Profit Margin of American Bio Medica is -154.44 % in 2022.

Net Profit Margin of American Bio Medica changed from -20.87 % to -154.44 %, representing a 639.82% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin American Bio Medica since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's American Bio Medica with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — American Bio Medica

All Key Metrics — American Bio Medica